statin intolerant patient

T2DM

Hypercholesteremia

ASCVD

LDL-C goal achievement in 91% patients

15% more LDL -c reduction than monotherapy

Prevents Cardiovascular events even at the age of 75 or more

Reduce 13% more Plaque volume.

Rosukem F

Rosukem CV

Rosukem A

Rosukem Gold

Rosukem EZ

Rosukem 5/10/20

For CVD prevention in patient with hypercholesterolemia

For CVD prevention in T2DM patients

For CVD prevention post PCI / CABG

Patients who are unable to achieve LDL-C goal despite of statin monotherapy

For secondary prevention of ASCVD

●inhibits HMG CoA reductase enzyme in liver

●It  binds and blocks the mediator of cholesterol absorption, Niemann-Pick C1-Like 1 (NPC1L1) transporter protein on epithelial cells of intestinal tract

Blocks alpha Glucosidase Receptor

Block sulphonamide receptor in b-cells

●It  binds and blocks the mediator of cholesterol absorption, Niemann-Pick C1-Like 1 (NPC1L1) transporter protein on epithelial cells of intestinal tract

●inhibits HMG CoA reductase enzyme in liver

Reduces HGO, increases Insulin sensitivity

peripheral utilization of glucose.

Induces PPAR - gamma & alpha

18 clinical trials & 63000 Patients

20 clinical trials & 65000 Patients

15 clinical trials & 60000 Patients

17 clinical trials & 62000 Patients

19 clinical trials & 64000 Patients

Hepatoselectivity, Hydrophilicity

reduces total Arethoma value by -6.3 compared to -4.4 of high intensity Atorvastatin.

superior to atorvastatin in the reversion of coronary atherosclerotic plaques

●Increase fibrous cap thickness and decreases macrophages line arc

better reduction of LDL-c

Rosuvastatin 10 mg + Ezetimibe 10 mg

Rosuvastatin 5mg + Ezetimibe 10 mg

Rosuvastatin 40 mg + Ezetimibe 10 mg

Rosuvastatin 20 mg + Ezetimibe 10 mg